Switzerland Innovation Park Basel Area Site Novartis Campus
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.
Novartis Campus in Basel (img: Mark Niedermann)
In addition to being positioned at the very heart of the Novartis Campus, the site offers fix desks as well as flex desks, a workshop area, an agile workplace and a meeting area. The open space stimulates collaboration.
We particularly invite startups and companies active in the field of digital healthcare and personalized medicine to get in touch with our Community Manager Rahel Schneider to visit our site of the Switzerland Innovation Park Basel Area at the Novartis Campus.
The Switzerland Innovation Park Basel Area maintains four sites, located in Allschwil, Basel and Delémont. The site at the Novartis Campus is the latest addition. In January, the pharmaceutical company communicated the opening of the Campus. Basel Area Business & Innovation with the Switzerland Innovation Park Basel Area is the first external organization to move onto the Campus. The Switzerland Innovation Park Basel Area belongs to the national network of Switzerland Innovation, striving to offer the best place for technology-driven companies to develop their next product and providing easy access to talents, knowledge and expertise.
Share this article
You may also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More